87 related articles for article (PubMed ID: 28926903)
1. [Pharmacotherapy for pancreatic cancer: Difficulties and prospects].
Wang ZH; Zhou J; Shen L
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):712-716. PubMed ID: 28926903
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent.
Fountzilas C; Chhatrala R; Khushalani N; Tan W; LeVea C; Hutson A; Tucker C; Ma WW; Warren G; Boland P; Iyer R
Cancer Chemother Pharmacol; 2017 Sep; 80(3):497-505. PubMed ID: 28702772
[TBL] [Abstract][Full Text] [Related]
3. [Current status and future prospect of pharmacotherapy for pancreatic cancer].
Fang Y; Lai MR; Ge YQ; Zhang GJ; Cheng RB
Zhongguo Zhong Yao Za Zhi; 2019 Apr; 44(8):1509-1516. PubMed ID: 31090312
[TBL] [Abstract][Full Text] [Related]
4. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
Philip PA; Lutz MP
Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
[TBL] [Abstract][Full Text] [Related]
5. Current status of chemotherapy for advanced pancreatic and gastric cancer.
O'Connell MJ
J Clin Oncol; 1985 Jul; 3(7):1032-9. PubMed ID: 3894585
[TBL] [Abstract][Full Text] [Related]
6. A review of systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
[TBL] [Abstract][Full Text] [Related]
7. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
Saif MW
Anticancer Res; 2011 Mar; 31(3):1039-42. PubMed ID: 21498735
[TBL] [Abstract][Full Text] [Related]
8. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
9. [Problems of antineoplastic chemotherapy of pancreatic cancer].
Matthias M; Wolff H
Zentralbl Chir; 1987; 112(21):1322-36. PubMed ID: 3324556
[TBL] [Abstract][Full Text] [Related]
10. Treatment for pancreatic cancer: current therapy and continued progress.
Lockhart AC; Rothenberg ML; Berlin JD
Gastroenterology; 2005 May; 128(6):1642-54. PubMed ID: 15887156
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
13. Old and new drugs in systemic therapy of pancreatic cancer.
Pasetto LM; Jirillo A; Stefani M; Monfardini S
Crit Rev Oncol Hematol; 2004 Feb; 49(2):135-51. PubMed ID: 15012974
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
15. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.
Jensen LH
Expert Opin Investig Drugs; 2016; 25(3):359-65. PubMed ID: 26781267
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Kim MK; Yee J; Cho YS; Jang HW; Han JM; Gwak HS
BMC Cancer; 2018 Oct; 18(1):988. PubMed ID: 30326853
[TBL] [Abstract][Full Text] [Related]
17. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer.
Kelsen D
Semin Oncol; 1994 Aug; 21(4 Suppl 7):58-66. PubMed ID: 8091242
[TBL] [Abstract][Full Text] [Related]
18. [TS-1: S-1 based chemotherapy for far-advanced or relapsed pancreatic cancer].
Hayashi K; Uchida K; Hatori T; Takasaki K
Nihon Rinsho; 2006 Jan; 64 Suppl 1():194-7. PubMed ID: 16457248
[No Abstract] [Full Text] [Related]
19. [Locoregional and systemic therapy of advanced pancreatic carcinoma].
Gebauer T; Ridwelski K; Fahlke J; Lippert H
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1344-7. PubMed ID: 9931877
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib in pancreatic cancer: are tumor cells the (only) target?
Normanno N; De Luca A
J Clin Oncol; 2007 Dec; 25(36):5836-7. PubMed ID: 18089885
[No Abstract] [Full Text] [Related]
[Next] [New Search]
